COMPUTEX-TAIPEI
8.2.2021 07:17:09 CET | Business Wire | Press release
Asia’s largest ICT show, COMPUTEX Taipei, is rolling out its first in Online-Merge-Offline (OMO) hybrid exhibition this year. COMPUTEX 2021 Hybrid combines the onsite exhibition with #COMPUTEXVirtual for an exceptionally vibrant, accessible, comprehensive show and customer experience. In addition, #InnoVEXVirtual will be held on a parallel track. Through the virtual experiences, COMPUTEX aims to help industry leaders and startup companies get the best exhibition performance results and greatest value.
COMPUTEX onsite Exhibition
The onsite COMPUTEX will take place at the Taipei Nangang Exhibition Center, Hall 1 & 2, from June 1-4. This year’s exhibition will revolve around seven major themes: 5G, AI & IoT, Edge Computing, High-Performance Computing (HPC), Cyber Security, Gaming, and Innovations & Startups. These themes showcase Taiwan’s historical and future supply chain dominance throughout the global ICT industry.
InnoVEX will debut at Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1) as a global startup stage to display inventions that stand to reshape the technology landscape worldwide.
#COMPUTEXVirtual Online Exhibition
#COMPUTEXVirtual will take place from May 31-June 30 online with #InnoVEXVirtual as a part of the online show. Together, the online exhibition will highlight the following four features:
- Tech Insights:
COMPUTEX Forum, InnoVEX Forum, keynote speeches from leading companies, live demonstrations and related webinars will be available via live-streaming. These resources will reveal the latest technology trends with insights into what’s next for the tech industry.
- Virtual Display:
Exhibitors will showcase their products at virtual booths via videos and images. Provided contact information allows exhibitors to seize every opportunity to generate leads without the hindrance of any time differences.
- Matchmaking and Networking:
Video conferencing, meeting requests and instant messaging make it possible to break down barriers across countries and establish the most effective, timely communication channels for exhibitors and buyers.
- Hyper-Personalized Recommendation:
#COMPUTEXVirtual will use AI technology to identify user behaviors and provide interesting marketing strategies to exhibitors. Hyper-Personalized Recommendations will help increase the matchmaking accuracy and shape brand perception.
COMPUTEX Hybrid Webinars to be held on March 3.
#COMPUTEXVirtual and #InnoVEXVirtual are now open for registration. To demonstrate how the online events leverage cutting-edge technologies to overcome time and geographical limitations, the event organizer, Taiwan External Trade Development Council, will hold international webinars on March 3.
- #COMPUTEXVirtual exhibitor registration:
https://events.taiwantrade.com/CVirtual01
- #InnoVEXVirtual exhibitor registration:
https://events.taiwantrade.com/IVirtual01
- COMPUTEX Hybrid Webinars:
https://events.taiwantrade.com/CVirtual02
For more update：
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website: https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210207005039/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom